Establishment and characterization of 7 novel hepatocellular carcinoma cell lines from patient-derived tumor xenografts

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Xin, Hong ^b   Wang, Ke ^a   Hu, Gang ^a   Xie, Fubo ^a   Ouyang, Kedong ^a   Tang, Xuzhen ^a   Wang, Minjun ^b   Wen, Danyi ^a   Zhu, Yizhun ^b   Qin, Xiaoran ^a  

^a Shanghai ChemPartner Co Ltd   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; ERLOTINIB; GEMCITABINE; KI 67 ANTIGEN; OXALIPLATIN; RETINOIC ACID; RETINOIC ACID INDUCIBLE PROTEIN 3; SORAFENIB; UNCLASSIFIED DRUG; VIMENTIN; VINBLASTINE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BACTERIUM CONTAMINATION; CANCER CELL; CANCER CELL CULTURE; CARCINOGENICITY; CELL CYCLE; CELL HETEROGENEITY; CELL STRAIN CPL0903; CELL STRAIN LIXC002; CELL STRAIN LIXC003; CELL STRAIN LIXC004; CELL STRAIN LIXC006; CELL STRAIN LIXC011; CELL STRAIN LIXC012; CELL STRUCTURE; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; DRUG SCREENING; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MIDDLE AGED; MOUSE; MULTIDRUG RESISTANCE; MYCOPLASMA; NONHUMAN; SCID MOUSE; SHORT TANDEM REPEAT; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; CHROMOSOME ABERRATIONS; FEMALE; FOUNDER EFFECT; GENE EXPRESSION; HETEROGRAFTS; HUMANS; KARYOTYPING; LIVER NEOPLASMS; MALE; MICE; MICE, SCID; NEOPLASM PROTEINS; ORGAN SPECIFICITY; PRIMARY CELL CULTURE; TANDEM REPEAT SEQUENCES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84897454901     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085308     Document Type: Article

References (40)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA: a cancer journal for clinicians 61: 69-90.
2. Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP (2006) The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. Journal of hepatology 45: 529-538. (Pubitemid 44307383)
3. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, et al. (1993) Risk factors for hepatocellular carcinoma among patients with chronic liver disease. New England journal of medicine 328: 1797-1801. (Pubitemid 23174709)
4. Velazquez RF, Rodriguez M, Navascués CA, Linares A, Pérez R, et al. (2003) Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 37: 520-527. (Pubitemid 36258772)
5. El-Serag HB (2012) Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142: 1264-1273. e1261.
6. Bosch FX, Ribes J, Díaz M, Cléries R (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127: S5.
7. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42: 1208-1236. (Pubitemid 43112690)
8. Marquardt JU, Galle PR, Teufel A (2012) Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies. Journal of hepatology 56: 267-275.
9. W Wiedmann M, Mossner J (2011) Molecular Targeted Therapy of Hepatocellular Carcinoma-Results of the First Clinical Studies. Current cancer drug targets 11: 714-733.
10. Fransvea E, Paradiso A, Antonaci S, Giannelli G (2009) HCC heterogeneity: molecular pathogenesis and clinical implications. Analytical Cellular Pathology 31: 227-233.
11. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, et al. (2012) Patient-derived tumour xenografts as models for oncology drug development. Nature reviews Clinical oncology 9: 338-350.
12. Siolas D, Hannon GJ (2013) Patient Derived Tumor Xenografts: transforming clinical samples into mouse models. Cancer research.
13. Hu G, Li F, Ouyang K, Xie F, Tang X, et al. (2011) Intrinsic gemcitabine resistance in a novel pancreatic cancer cell line is associated with cancer stem cell-like phenotype. International journal of oncology.
14. Mizejewski G. β-Fetoprotein as a Biologic Response Modifier: Relevance to Domain and Subdomain Structure; 1997. Royal Society of Medicine. pp. 333-362.
15. Ni X, Bai X, Mao Y, Shao Y, Wu J, et al. (2005) The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. European Journal of Surgical Oncology (EJSO) 31: 164-169. (Pubitemid 40214752)
16. Guzman G, Alagiozian-Angelova V, Layden-Almer JE, Layden TJ, Testa G, et al. (2005) p53, Ki-67, and serum alpha feto-protein as predictors of hepatocellular carcinoma recurrence in liver transplant patients. Modern pathology 18: 1498-1503. (Pubitemid 41509405)
17. Hu L, Lau SH, Tzang C-H, Wen J-M, Wang W, et al. (2004) Association of Vimentin overexpression and hepatocellular carcinoma metastasis. Oncogene 23: 298-302. (Pubitemid 38142264)
18. Polakis P (2000) Wnt signaling and cancer. Genes & development 14: 1837-1851.
19. Goff L (2013) Targeting the HGF-cMET Axis in Hepatocellular Carcinoma. International journal of hepatology 2013.
20. Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, et al. (1995) Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer research 55: 2266-2269.
21. Naguib A, Trotman LC (2013) PTEN plasticity: how the taming of a lethal gene can go too far. Trends in cell biology.
22. Tao Q, Cheng Y, Clifford J, Lotan R (2004) Characterization of the murine orphan G-protein-coupled receptor gene, 〈i〉 Rai3〈/i〉 and its regulation by retinoic acid. Genomics 83: 270-280. (Pubitemid 38050116)
23. Tanaka M, Katayama F, Kato H, Tanaka H, Wang J, et al. (2011) Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. Journal of Epidemiology 21: 401-416.
24. Reid YA (2011) Characterization and authentication of cancer cell lines: an overview. Cancer Cell Culture: Springer. pp. 35-43.
25. Lok AS, Lai CL (1989) a-fetoprotein monitoring in chinese patients with chronic hepatitis B virus infection: Role in the early detection of hepatocellular carcinoma. Hepatology 9: 110-115. (Pubitemid 19046312)
26. Chan SL, Mo FK, Johnson PJ, Hui EP, Ma BB, et al. (2009) New utility of an old marker: serial a-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. Journal of Clinical Oncology 27: 446-452.
27. Tangkijvanich P, Anukulkarnkusol N, Suwangool P, Lertmaharit S, Hanvivatvong O, et al. (2000) Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. Journal of clinical gastroenterology 31: 302-308.
28. Singal A, Volk M, Waljee A, Salgia R, Higgins P, et al. (2009) Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Alimentary pharmacology & therapeutics 30: 37-47.
29. Ertle JM, Heider D, Wichert M, Keller B, Kueper R, et al. (2013) A Combination of a-Fetoprotein and Des-c-Carboxy Prothrombin Is Superior in Detection of Hepatocellular Carcinoma. Digestion 87: 121-131.
30. Carr BI, Kanke F, Wise M, Satomura S (2007) Clinical evaluation of Lens culinaris agglutinin-reactive a-fetoprotein and des-c -carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Digestive diseases and sciences 52: 776-782.
31. Ivaska J (2011) Vimentin: Central hub in EMT induction? Small Gtpases 2: 51-53.
32. de Lera AR, Bourguet W, Altucci L, Gronemeyer H (2007) Design of selective nuclear receptor modulators: RAR and RXR as a case study. Nature Reviews Drug Discovery 6: 811-820. (Pubitemid 47504872)
33. Sun S-Y, Lotan R (2002) Retinoids and their receptors in cancer development and chemoprevention. Critical reviews in oncology/hematology 41: 41-55. (Pubitemid 34051581)
34. Gao T, He B, Pan Y, Li R, Xu Y, et al. (2013) The association of retinoic acid receptor beta2(RARbeta2) methylation status and prostate cancer risk: a systematic review and meta-analysis. PloS one 8: e62950.
35. Mukhopadhyay B, Liu J, Osei-Hyiaman D, Godlewski G, Mukhopadhyay P, et al. (2010) Transcriptional regulation of cannabinoid receptor-1 expression in the liver by retinoic acid acting via retinoic acid receptor-gamma. J Biol Chem 285: 19002-19011.
36. Yu M-W, Hsieh H-H, Pan W-H, Yang C-S, Chen C-J (1995) Vegetable consumption, serum retinol level, and risk of hepatocellular carcinoma. Cancer research 55: 1301-1305.
37. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. New England journal of medicine 359: 378-390.
38. Reig M, Bruix J (2009) Sorafenib for hepatocellular carcinoma: global validation. Gastroenterology 137: 1171.
39. Julien S, Merino-Trigo A, Lacroix L, Pocard M, Goéré D, et al. (2012) Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clinical Cancer Research 18: 5314-5328.
40. Maletzki C, Stier S, Gruenert U, Gock M, Ostwald C, et al. (2012) Establishment, Characterization and Chemosensitivity of Three Mismatch Repair Deficient Cell Lines from Sporadic and Inherited Colorectal Carcinomas. PloS one 7: e52485.